Clinicians report that early AKT inhibition side effects are manageable, allowing four out of five patients to maintain ...

Akeega prostate cancer UK approval: the MHRA has licensed Johnson and Johnson's niraparib-abiraterone combination for men ...

In this long-term follow-up to the phase 2 ARTO trial, researchers analyzed survival outcomes in patients with CRPC treated with metastasis-directed therapy.

Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer. We evaluated the clinical benefit of ...

An update of the COU-AA-301 study confirms a survival advantage with abiraterone–prednisone compared to prednisone in post-docetaxel patients with metastatic castration-resistant prostate cancer. We ...

Enzalutamide resistance could result from raised androgens and be overcome by combination with abiraterone acetate. PLATO (ClinicalTrials.gov identifier: NCT01995513) interrogated this hypothesis ...

Men diagnosed with metastatic hormone-sensitive prostate cancer who carry a specific tumor deficiency now have a targeted ...

From Choosing Wisely to Using Wisely: Increasing the Value of Cancer Care Through Clinical Research Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus ...

Abiraterone acetate is used along with prednisolone (corticosteroid) for treating a type of prostate cancer called metastatic castration-resistant prostate cancer (mCRPC) previously called ...

Lynparza plus abiraterone was approved by the FDA for the treatment of patients with deleterious or suspected BRCA-mutated metastatic castration-resistant prostate cancer. The Food and Drug ...

Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, ...